TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2403850
Drug: succinylcholine 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 0.50 mg.kg‐1
Study: 2403850
Drug: succinylcholine 1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1.00 mg.kg‐1
Study: 2403850
Drug: succinylcholine (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine (various doses)
Study: 734314
Drug: Indomethacin, 100
Normalized name: Indomethacin, 100 mg rectal suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 100 mg orally
Study: 734314
Drug: Prednisolone, 5
Normalized name: PrednisoLONE, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone, 5 mg
Study: 26797810
Drug: Hydronidone 15-120
Normalized name: hydrocodone bitartrate 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydronidone 15-120 mg single dose
Study: 26797810
Drug: Hydronidone 90
Normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydronidone 90 and 120 mg thrice daily for 7 days
Study: 26797810
Drug: Hydronidone 60
Normalized name: Hydronidone
DrugBank: Hydronidone (DB06299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydronidone 60 mg thrice daily for 28 days
Study: 26797810
Drug: Hydronidone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydronidone (all doses)
Study: 25385061
Drug: topical artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical artificial tear substitute (placebo)
Study: 19470311
Drug: Immediate Treatment
Normalized name: Aquaphor Immediate Relief Lip Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Treatment group (7 clinic visits across 18 months)
Study: 19470311
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment group (9 clinic visits across 24 months)
Study: 15570076
Drug: FOLFOX4 (LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4 (LV and FU plus oxaliplatin 85 mg/m2 IV over 2 hours on day 1)
Study: 15570076
Drug: LV5FU2 (LV
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 (LV 200 mg/m2 IV and FU 400 mg/m2 IV bolus, followed by FU 600 mg/m2 IV over 22 hours on days 1 and 2)
Study: 11234669
Drug: Tinzaparin (175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinzaparin (175 anti‐Xa IU/kg) administered subcutaneously once daily for 10 days
Study: 9087473
Drug: Alendronate (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (dose higher than 1 mg per day)
Study: 7655702
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment with beta-agonists (unspecified dosage and duration)
Study: 7655702
Drug: As-needed beta-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: As-needed beta-agonists (unspecified dosage and duration)
Study: 7655702
Drug: Fenoterol (unspecified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (unspecified dosage)
Study: 7655702
Drug: Salbutamol (unspecified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (unspecified dosage)
Study: 1972850
Drug: roxithromycin 300
Normalized name: roxithromycin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 300 mg once a day
Study: 1972850
Drug: erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: erythromycin 500 mg twice a day
Study: 28702451
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of prone and supine (SIPS)
Study: 19025625
Drug: Dynamic arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic arterial line pressure (DALP) based prescription of Qb (300-500 mL/min)
Study: 16189075
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen (trimethoprim, sulfamethoxazole, doxycycline, and chloramphenicol)
Study: 16189075
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (trimethoprim-sulfamethoxazole and doxycycline)
Study: 30403937
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen
Study: 16189075
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of oral therapy
Study: 12651645
Drug: Clonidine 5
Normalized name: apraclonidine 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 5 micro g/kg
Study: 10651656
Drug: Pentasa 1
Normalized name: Pentasa 10 MG/ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa 1 g sachet (unit dose, microgranules in a foil bag)
Study: 10651656
Drug: Pentasa 500
Normalized name: Pentasa 500mg Extended-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa 500 mg tablets (2 x 500 mg)
Study: 2254831
Drug: 0.04% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.04% CHX daily home marginal irrigation + 0.12% CHX professional irrigation
Study: 2254831
Drug: Water daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water daily home marginal irrigation + 0.12% CHX professional irrigation
Study: 2254831
Drug: Water daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water daily home marginal irrigation + water professional irrigation
Study: 6104554
Drug: Atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (50 mg 3 times a day)
Study: 531563
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg twice daily)
Study: 6104554
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg 3 times a day)
Study: 6104554
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg 3 times a day)
Study: 26152568
Drug: Multifaceted feedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted feedback strategy (extensive monthly feedback reports, outreach visits, quality improvement team)
Study: 21890092
Drug: Nesiritide infusions
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nesiritide infusions
Study: 19218044
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA), 40 mg twice daily for 2 months
Study: 15310997
Drug: Dutasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (5 mg per day for 6 to 10 weeks)
Study: 9663367
Drug: Venlafaxine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (200 mg/d)
Study: 29097299
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (100mg daily)
Study: 24074852
Drug: Change from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change from post-treatment through follow-up
Study: 21072246
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg orally twice daily plus zanamivir 10 mg by inhalation twice daily (OZ)
Study: 21072246
Drug: Oseltamivir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir plus inhaled placebo (O)
Study: 21072246
Drug: Zanamivir plus
Normalized name: Zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zanamivir plus oral placebo (Z)
Study: 18990048
Drug: Integrated acupuncture,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated acupuncture, tuina, and rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks (Group I)
Study: 18990048
Drug: Rehabilitation (physiotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation (physiotherapy, occupational therapy, and hydrotherapy) for 12 weeks followed by acupuncture and tuina for 12 weeks (Group II)
Study: 18990048
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (both groups)
Study: 9417514
Drug: Fluconazole (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (100 mg/d)
Study: 1308663
Drug: Ketoconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (200 mg/d)
Study: 31310160
Drug: Long-term methimazole
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term methimazole therapy (60-120 months)
Study: 31310160
Drug: Conventional methimazole
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional methimazole therapy (18-24 months)
Study: 22924638
Drug: FFR-guided PCI
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR-guided PCI plus the best available medical therapy
Study: 22924638
Drug: Best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Best available medical therapy alone
Study: 22924638
Drug: Registry patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Registry patients (best available medical therapy)
Study: 19330342
Drug: EE/CA-metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE/CA-metformin
Study: 19394976
Drug: metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin alone
Study: 9689432
Drug: Nutrient-mixture (Aminoleban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrient-mixture (Aminoleban EN) 100 g/day for 2 to 6 weeks
Study: 2777728
Drug: Intravenous gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin and 12 g/day piperacillin
Study: 2777728
Drug: Intravenous gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin and 8 g/day piperacillin
Study: 2777728
Drug: Intravenous gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gentamicin and piperacillin (both doses)
Study: 2777728
Drug: Further antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further antibiotics added to unresponsive patients
Study: 28814835
Drug: Generic formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic formulation of atorvastatin (Atorva®) 20 mg once daily
Study: 28814835
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of atorvastatin (Lipitor®) 20 mg once daily
Study: 18823024
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) alone
Study: 12820466
Drug: Intraarterial continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial continuous infusion of cisplatin (CDDP), 24 mg/m2/day
Study: 12820466
Drug: Bolus of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of cisplatin (CDDP), 24 mg/m2/day
Study: 12820466
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms received i.v. escalating doses of fluorouracil
Study: 8839635
Drug: New delayed-release
Normalized name: bisacodyl Delayed Release Oral Tablet [Correct (New Formula)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New delayed-release formulation of UDCA
Study: 8839635
Drug: Traditional pH-dependent
Normalized name: PH-284
DrugBank: PH-284 (DB05452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional pH-dependent sequential release formulation of UDCA
Study: 6421010
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg buccal nitroglycerin
Study: 6421010
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg buccal nitroglycerin
Study: 6421010
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg buccal nitroglycerin
Study: 6421010
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg sublingual nitroglycerin
Study: 28196503
Drug: G-MISS questionnaire
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-MISS questionnaire
Study: 22822451
Drug: NuFit active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NuFit active blend (2.25 g leucine and 30 mg pyridoxine)
Study: 19535190
Drug: Nicorandil, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil, 15 mg/d
Study: 14673047
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus chemotherapy (cisplatin 80 mg/m2 x 1 day and fluorouracil 800 mg/m2 x 5 days)
Study: 1610576
Drug: Methohexital anesthesia
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital anesthesia (0.5 to 1.0 mg/kg) with atropine premedication
Study: 1610576
Drug: Methohexital anesthesia
Normalized name: Methohexital
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexital anesthesia (0.5 to 1.0 mg/kg)
Study: 6148881
Drug: Nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (80 to 320 mg for 6 weeks)
Study: 31517543
Drug: Child STEPs
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child STEPs treatment program
Study: 30845320
Drug: Vi-Typhoid Conjugate
Normalized name: typhoid Vi polysaccharide vaccine, S typhi Ty2 strain
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-Typhoid Conjugate Vaccine (Vi-TCV)
Study: 30845320
Drug: Meningococcal serogroup
Normalized name: MENINGOCOCCAL B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal serogroup A conjugate vaccine (control)
Study: 29524194
Drug: Low-Se diet
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Se diet (−Se group, 0.033 mg/kg Se)
Study: 29524194
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet (control group, 0.2 mg/kg Se)
Study: 17159195
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenously every 6 months)
Study: 16371734
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment and selective ERCP +/‐ ES after 48 hours
Study: 23339958
Drug: Warfarin vs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin vs Aspirin
Study: 1295122
Drug: Nitrendipine (Nidrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (Nidrel 20 mg) administered once daily in the morning
Study: 1295122
Drug: Nitrendipine (Nidrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (Nidrel 20 mg) administered once daily in the evening
Study: 1295122
Drug: Nitrendipine (Nidrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (Nidrel 20 mg) administered once daily (both morning and evening)
Study: 29458218
Drug: Curcuminoids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids plus piperine (500 mg/day curcuminoids and 5 mg/day piperine)
Study: 24121756
Drug: TMC310911 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 75 mg bid
Study: 24121756
Drug: TMC310911 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 150 mg bid
Study: 24121756
Drug: TMC310911 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 300 mg bid
Study: 24121756
Drug: TMC310911 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC310911 300 mg qd
Study: 23145859
Drug: Ceftazidime-avibactam 500
Normalized name: avibactam
DrugBank: Avibactam (DB09060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime-avibactam 500 mg plus avibactam 125 mg every 8 hours for 7-14 days
Study: 23145859
Drug: Imipenem-cilastatin 500
Normalized name: imipenem-cilastatin 500 mg-500 mg injectable powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin 500 mg every 6 hours for 7-14 days
Study: 21030934
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) for secondary prevention
Study: 21030934
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) for primary prevention
Study: 21030934
Drug: Consideration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consideration of ASA prescription
Study: 18572751
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 10 mg/day
Study: 2044551
Drug: Anistreplase (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anistreplase (30 U intravenous injection over 2-5 minutes)
Study: 2044551
Drug: Streptokinase (1,500,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase (1,500,000 U intravenous infusion over 60 minutes)
Study: 7025638
Drug: Dexamethasone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (20 mg, 5 mg every 12 hours, intramuscularly)
Study: 27916480
Drug: A1 proteinase
Normalized name: Human alpha1 proteinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: A1 proteinase inhibitor (A1PI) treatment (60 mg/kg per week)
Study: 24627921
Drug: Restricted intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restricted intravenous fluid regimen (R group)
Study: 16645442
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at the rate of 1-8 mug . kg . min for 15-20 min
Study: 12965108
Drug: Acarbose 50
Normalized name: acarbose 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 50 mg t.i.d. for 16 weeks
Study: 10907674
Drug: Placebo (maltodextrin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (maltodextrin, 100 mg)
Study: 8836952
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg melatonin
Study: 16263827
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg melatonin
Study: 8836952
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg melatonin
Study: 8836952
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg melatonin
Study: 6438674
Drug: Diazepam (Valium)
Normalized name: diazepam Oral Tablet [Valium]
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam (Valium) administration
Study: 29469177
Drug: Levosimendan infusion
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan infusion (24 hours)
Study: 24758641
Drug: Delayed oocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oocyte maturation trigger (24 hours later) in patients with low progesterone (<= 1 ng/ml)
Study: 24758641
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same day trigger) in patients with low progesterone (<= 1 ng/ml)
Study: 24758641
Drug: Delayed oocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed oocyte maturation trigger (24 hours later) in patients with elevated progesterone (> 1 ng/ml)
Study: 24758641
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same day trigger) in patients with elevated progesterone (> 1 ng/ml)
Study: 20435234
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg
Study: 25450709
Drug: Entecavir 0.5
Normalized name: entecavir 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 0.5 mg
Study: 16630123
Drug: Concurrent R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent R-CHOP (6 courses of CHOP concurrently with rituximab)
Study: 16630123
Drug: Sequential R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential R-CHOP (6 courses of CHOP followed by 6 courses of weekly rituximab)
Study: 14649479
Drug: Detection of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detection of minimal residual disease (MRD) by identifying clone-specific T-cell receptor (TCR) or immunoglobulin (Ig) gene rearrangements
Study: 14649479
Drug: Standardized tools
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized tools for treatment response evaluation
Study: 9062865
Drug: Melatonin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (1 mg)
Study: 3283229
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium intake (1400 mg/day: 400‐mg calcium diet plus two 500‐mg calcium tablets/day)
Study: 3283229
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium intake (400 mg calcium diet plus two placebo tablets/day)
Study: 31436886
Drug: Daily naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily naltrexone
Study: 23369075
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (supervised exercise training twice weekly for eight weeks)
Study: 23369075
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (weekly telephone support)
Study: 15291653
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of fluvoxamine (50 mg/day) plus low-dose clozapine (≤ 250 mg/day)
Study: 15291653
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with clozapine (≤ 600 mg/day)
Study: 8429114
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg, four times daily)
Study: 8429114
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg, twice daily)
Study: 31677703
Drug: Saffron (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron (15 mg/d)
Study: 29247154
Drug: Golimumab (GOL)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GOL) 2 mg/kg administered intravenously at weeks 0, 4, 12, and every 8 weeks
Study: 29247154
Drug: Golimumab (GOL)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GOL) 2 mg/kg administered intravenously
Study: 29247154
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) administered intravenously